vs
Celularity Inc（CELU）与Digimarc CORP（DMRC）财务数据对比。点击上方公司名可切换其他公司
Digimarc CORP的季度营收约是Celularity Inc的1.7倍（$8.9M vs $5.3M），Digimarc CORP净利率更高（-47.2% vs -436.7%，领先389.5%），Digimarc CORP同比增速更快（2.9% vs -43.2%），过去两年Digimarc CORP的营收复合增速更高（-5.3% vs -33.9%）
Celularity Inc是一家临床阶段生物技术企业，专注于开发胎盘来源的即用型细胞疗法与免疫疗法，用于治疗癌症、自身免疫性疾病及退行性疾病，主要面向美国市场，产品管线覆盖肿瘤学、再生医学、传染病等领域。
迪吉马克公司是一家企业软件与服务提供商，其主打产品包含带数字标识符的软件，主要用于解决防伪问题、验证产品真伪、提升回收准确性以及实现供应链可追溯，产品可广泛应用于服装、快消品、美妆健康、汽车等多个行业领域。
CELU vs DMRC — 直观对比
营收规模更大
DMRC
是对方的1.7倍
$5.3M
营收增速更快
DMRC
高出46.0%
-43.2%
净利率更高
DMRC
高出389.5%
-436.7%
两年增速更快
DMRC
近两年复合增速
-33.9%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $5.3M | $8.9M |
| 净利润 | $-23.1M | $-4.2M |
| 毛利率 | 26.1% | 63.5% |
| 营业利润率 | -244.1% | -48.2% |
| 净利率 | -436.7% | -47.2% |
| 营收同比 | -43.2% | 2.9% |
| 净利润同比 | -43.3% | 51.4% |
| 每股收益（稀释后） | $-0.88 | $-0.18 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CELUDMRC
| Q4 25 | — | $8.9M | ||
| Q3 25 | $5.3M | $7.6M | ||
| Q2 25 | $5.7M | $8.0M | ||
| Q1 25 | $11.4M | $9.4M | ||
| Q4 24 | $18.1M | $8.7M | ||
| Q3 24 | $9.3M | $9.4M | ||
| Q2 24 | $12.1M | $10.4M | ||
| Q1 24 | $14.7M | $9.9M |
净利润CELUDMRC
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $-23.1M | $-8.2M | ||
| Q2 25 | $-24.5M | $-8.2M | ||
| Q1 25 | $-19.8M | $-11.7M | ||
| Q4 24 | $-13.3M | $-8.6M | ||
| Q3 24 | $-16.1M | $-10.8M | ||
| Q2 24 | $-6.5M | $-9.3M | ||
| Q1 24 | $-22.0M | $-10.3M |
毛利率CELUDMRC
| Q4 25 | — | 63.5% | ||
| Q3 25 | 26.1% | 58.3% | ||
| Q2 25 | 8.6% | 58.8% | ||
| Q1 25 | 68.9% | 65.0% | ||
| Q4 24 | 59.5% | 60.8% | ||
| Q3 24 | 58.2% | 62.4% | ||
| Q2 24 | 82.5% | 66.1% | ||
| Q1 24 | 88.8% | 62.5% |
营业利润率CELUDMRC
| Q4 25 | — | -48.2% | ||
| Q3 25 | -244.1% | -109.7% | ||
| Q2 25 | -276.6% | -105.2% | ||
| Q1 25 | -91.8% | -128.9% | ||
| Q4 24 | -51.2% | -105.1% | ||
| Q3 24 | -124.0% | -120.4% | ||
| Q2 24 | -84.0% | -96.2% | ||
| Q1 24 | -50.2% | -109.2% |
净利率CELUDMRC
| Q4 25 | — | -47.2% | ||
| Q3 25 | -436.7% | -106.9% | ||
| Q2 25 | -427.5% | -102.6% | ||
| Q1 25 | -172.9% | -125.2% | ||
| Q4 24 | -73.3% | -99.9% | ||
| Q3 24 | -173.2% | -113.9% | ||
| Q2 24 | -53.6% | -89.3% | ||
| Q1 24 | -149.9% | -104.0% |
每股收益（稀释后）CELUDMRC
| Q4 25 | — | $-0.18 | ||
| Q3 25 | $-0.88 | $-0.38 | ||
| Q2 25 | $-1.02 | $-0.38 | ||
| Q1 25 | $-0.84 | $-0.55 | ||
| Q4 24 | $-0.58 | $-0.40 | ||
| Q3 24 | $-0.73 | $-0.50 | ||
| Q2 24 | $-0.30 | $-0.43 | ||
| Q1 24 | $-1.03 | $-0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $120.0K | $12.9M |
| 总债务越低越好 | $35.7M | — |
| 股东权益账面价值 | $-20.1M | $40.2M |
| 总资产 | $114.2M | $53.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CELUDMRC
| Q4 25 | — | $12.9M | ||
| Q3 25 | $120.0K | $12.6M | ||
| Q2 25 | $863.0K | $16.1M | ||
| Q1 25 | $293.0K | $21.6M | ||
| Q4 24 | $738.0K | $28.7M | ||
| Q3 24 | $133.0K | $33.7M | ||
| Q2 24 | $467.0K | $41.5M | ||
| Q1 24 | $1.9M | $48.9M |
总债务CELUDMRC
| Q4 25 | — | — | ||
| Q3 25 | $35.7M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CELUDMRC
| Q4 25 | — | $40.2M | ||
| Q3 25 | $-20.1M | $41.4M | ||
| Q2 25 | $-25.5M | $46.5M | ||
| Q1 25 | $-5.5M | $50.0M | ||
| Q4 24 | $8.8M | $61.4M | ||
| Q3 24 | $17.3M | $70.2M | ||
| Q2 24 | $27.8M | $77.2M | ||
| Q1 24 | $31.2M | $84.5M |
总资产CELUDMRC
| Q4 25 | — | $53.0M | ||
| Q3 25 | $114.2M | $55.4M | ||
| Q2 25 | $120.3M | $60.7M | ||
| Q1 25 | $128.9M | $66.5M | ||
| Q4 24 | $132.7M | $75.8M | ||
| Q3 24 | $128.8M | $85.0M | ||
| Q2 24 | $135.5M | $93.4M | ||
| Q1 24 | $143.8M | $99.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.2M | $991.0K |
| 自由现金流经营现金流 - 资本支出 | — | $895.0K |
| 自由现金流率自由现金流/营收 | — | 10.0% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-12.3M |
8季度趋势，按日历期对齐
经营现金流CELUDMRC
| Q4 25 | — | $991.0K | ||
| Q3 25 | $-4.2M | $-2.6M | ||
| Q2 25 | $-999.0K | $-4.7M | ||
| Q1 25 | $-3.0M | $-5.5M | ||
| Q4 24 | $1.6M | $-4.2M | ||
| Q3 24 | $-144.0K | $-7.1M | ||
| Q2 24 | $-3.4M | $-6.8M | ||
| Q1 24 | $-4.4M | $-8.4M |
自由现金流CELUDMRC
| Q4 25 | — | $895.0K | ||
| Q3 25 | — | $-2.8M | ||
| Q2 25 | — | $-4.9M | ||
| Q1 25 | — | $-5.5M | ||
| Q4 24 | $1.5M | $-4.2M | ||
| Q3 24 | — | $-7.2M | ||
| Q2 24 | $-3.5M | $-6.9M | ||
| Q1 24 | $-4.4M | $-8.5M |
自由现金流率CELUDMRC
| Q4 25 | — | 10.0% | ||
| Q3 25 | — | -36.9% | ||
| Q2 25 | — | -61.0% | ||
| Q1 25 | — | -59.1% | ||
| Q4 24 | 8.3% | -49.1% | ||
| Q3 24 | — | -75.7% | ||
| Q2 24 | -28.7% | -66.1% | ||
| Q1 24 | -30.3% | -85.8% |
资本支出强度CELUDMRC
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | — | 2.5% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.3% | 0.3% | ||
| Q1 24 | 0.3% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CELU
| License Royalty And Other | $2.9M | 56% |
| Degenerative Disease | $2.2M | 42% |
DMRC
| Subscription | $5.3M | 60% |
| The Government | $3.6M | 41% |
